Does the media favor GLUE or LXEO?

In the previous week, Monte Rosa Therapeutics had 17 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 20 mentions for Monte Rosa Therapeutics and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.59 beat Monte Rosa Therapeutics' score of 0.04 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LXEO or ABSI more profitable?

Lexeo Therapeutics has a net margin of 0.00% compared to Absci's net margin of -6,450.76%. Lexeo Therapeutics' return on equity of -47.48% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Absci -6,450.76% -66.32% -57.01%

Does the media refer more to LXEO or ABSI?

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Absci. MarketBeat recorded 3 mentions for Lexeo Therapeutics and 2 mentions for Absci. Lexeo Therapeutics' average media sentiment score of 0.59 beat Absci's score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, LXEO or MLTX?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is LXEO or MLTX more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media refer more to LXEO or MLTX?

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 6 mentions for MoonLake Immunotherapeutics and 3 mentions for Lexeo Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.59 beat Lexeo Therapeutics' score of 0.59 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LXEO or NVAX?

In the previous week, Novavax had 22 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 25 mentions for Novavax and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.59 beat Novavax's score of 0.22 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 5 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, ORIC or LXEO?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A

Is ORIC or LXEO more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Lexeo Therapeutics N/A -47.48% -41.72%

Does the media prefer ORIC or LXEO?

In the previous week, Oric Pharmaceuticals had 12 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 15 mentions for Oric Pharmaceuticals and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.59 beat Oric Pharmaceuticals' score of 0.30 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lexeo Therapeutics (LXEO) Competitors

$4.81 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$4.82 +0.01 (+0.21%)

As of 08/7/2026 07:47 PM Eastern

Compare

LXEO vs. GLUE, ABSI, MLTX, NVAX, and ORIC

Should you buy Lexeo Therapeutics stock or one of its competitors? MarketBeat compares Lexeo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexeo Therapeutics include Monte Rosa Therapeutics (GLUE), Absci (ABSI), MoonLake Immunotherapeutics (MLTX), Novavax (NVAX), and Oric Pharmaceuticals (ORIC). These companies are all part of the "biotechnology" industry.

How does Lexeo Therapeutics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Monte Rosa Therapeutics has higher revenue and earnings than Lexeo Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	10.95	-$38.63M	-$1.76	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

Monte Rosa Therapeutics presently has a consensus price target of $28.50, indicating a potential upside of 79.47%. Lexeo Therapeutics has a consensus price target of $18.75, indicating a potential upside of 289.81%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Lexeo Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Monte Rosa Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

In the previous week, Monte Rosa Therapeutics had 17 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 20 mentions for Monte Rosa Therapeutics and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.59 beat Monte Rosa Therapeutics' score of 0.04 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Monte Rosa Therapeutics beats Lexeo Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Absci?

Lexeo Therapeutics (NASDAQ:LXEO) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Lexeo Therapeutics has higher earnings, but lower revenue than Absci. Absci is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Absci	$2.80M	497.21	-$115.18M	-$0.83	N/A

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Absci. MarketBeat recorded 3 mentions for Lexeo Therapeutics and 2 mentions for Absci. Lexeo Therapeutics' average media sentiment score of 0.59 beat Absci's score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexeo Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Absci has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lexeo Therapeutics has a net margin of 0.00% compared to Absci's net margin of -6,450.76%. Lexeo Therapeutics' return on equity of -47.48% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Absci	-6,450.76%	-66.32%	-57.01%

Lexeo Therapeutics presently has a consensus price target of $18.75, indicating a potential upside of 289.81%. Absci has a consensus price target of $13.43, indicating a potential upside of 50.38%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Lexeo Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Lexeo Therapeutics beats Absci on 11 of the 16 factors compared between the two stocks.

How does Lexeo Therapeutics compare to MoonLake Immunotherapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Lexeo Therapeutics' return on equity of -47.48% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 6 mentions for MoonLake Immunotherapeutics and 3 mentions for Lexeo Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.59 beat Lexeo Therapeutics' score of 0.59 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexeo Therapeutics presently has a consensus price target of $18.75, indicating a potential upside of 289.81%. MoonLake Immunotherapeutics has a consensus price target of $24.21, indicating a potential upside of 32.61%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Lexeo Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Summary

Lexeo Therapeutics beats MoonLake Immunotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Novavax?

Lexeo Therapeutics (NASDAQ:LXEO) and Novavax (NASDAQ:NVAX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Novavax has higher revenue and earnings than Lexeo Therapeutics. Novavax is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Novavax	$1.12B	1.16	$440.30M	-$1.52	N/A

Lexeo Therapeutics presently has a consensus price target of $18.75, suggesting a potential upside of 289.81%. Novavax has a consensus price target of $13.00, suggesting a potential upside of 63.52%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Lexeo Therapeutics is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lexeo Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Novavax	-59.87%	-14.82%	-13.35%

In the previous week, Novavax had 22 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 25 mentions for Novavax and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.59 beat Novavax's score of 0.22 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	5 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Lexeo Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Novavax has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

Summary

Lexeo Therapeutics beats Novavax on 10 of the 16 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

In the previous week, Oric Pharmaceuticals had 12 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 15 mentions for Oric Pharmaceuticals and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.59 beat Oric Pharmaceuticals' score of 0.30 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

Oric Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Oric Pharmaceuticals' return on equity of -35.35% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Oric Pharmaceuticals currently has a consensus price target of $19.27, suggesting a potential upside of 42.76%. Lexeo Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 289.81%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Oric Pharmaceuticals and Lexeo Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Lexeo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXEO vs. The Competition

Export

Metric	Lexeo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$377.68M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-3.32	9.02	270.59	25.05
Price / Sales	N/A	1,294.46	599.45	84.15
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	1.42	17.61	11.21	6.43
Net Income	-$99.96M	-$13.25M	$3.45B	$348.10M
7 Day Performance	14.52%	4.99%	3.41%	2.68%
1 Month Performance	-0.21%	-2.13%	-0.71%	-0.83%
1 Year Performance	6.18%	61.28%	77.31%	23.97%

Lexeo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXEO Lexeo Therapeutics	1.9995 of 5 stars	$4.81 flat	$18.75 +289.8%	+6.2%	$377.68M	N/A	N/A	58	Upcoming Earnings Gap Down
GLUE Monte Rosa Therapeutics	2.9226 of 5 stars	$16.21 +5.4%	$30.67 +89.1%	+262.6%	$1.36B	$123.67M	N/A	90	Earnings Report Analyst Forecast
ABSI Absci	2.3685 of 5 stars	$8.42 +6.2%	$13.43 +59.5%	+214.4%	$1.32B	$2.80M	N/A	210	Negative News Upcoming Earnings Gap Up
MLTX MoonLake Immunotherapeutics	3.5803 of 5 stars	$17.55 +0.9%	$24.21 +37.9%	-65.2%	$1.29B	N/A	N/A	2
NVAX Novavax	2.3434 of 5 stars	$7.58 +2.3%	$13.00 +71.5%	-5.0%	$1.25B	$1.12B	N/A	1,990	Trending News Earnings Report Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXEO) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. GLUE, ABSI, MLTX, NVAX, and ORIC

How does Lexeo Therapeutics compare to Monte Rosa Therapeutics?

Summary

How does Lexeo Therapeutics compare to Absci?

Summary

How does Lexeo Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Lexeo Therapeutics compare to Novavax?

Summary

How does Lexeo Therapeutics compare to Oric Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. GLUE, ABSI, MLTX, NVAX, and ORIC

How does Lexeo Therapeutics compare to Monte Rosa Therapeutics?

Which has better valuation and earnings, GLUE or LXEO?

Do analysts recommend GLUE or LXEO?

Is GLUE or LXEO more profitable?

Do insiders & institutionals hold more shares of GLUE or LXEO?

Which has more risk & volatility, GLUE or LXEO?

Does the media favor GLUE or LXEO?

Summary

How does Lexeo Therapeutics compare to Absci?

Which has better valuation and earnings, LXEO or ABSI?

Does the media refer more to LXEO or ABSI?

Which has more volatility & risk, LXEO or ABSI?

Do insiders and institutionals believe in LXEO or ABSI?

Is LXEO or ABSI more profitable?

Do analysts recommend LXEO or ABSI?

Summary

How does Lexeo Therapeutics compare to MoonLake Immunotherapeutics?

Is LXEO or MLTX more profitable?

Does the media refer more to LXEO or MLTX?

Do analysts rate LXEO or MLTX?

Which has more risk and volatility, LXEO or MLTX?

Do insiders and institutionals hold more shares of LXEO or MLTX?

Which has higher valuation and earnings, LXEO or MLTX?

Summary

How does Lexeo Therapeutics compare to Novavax?

Which has better valuation and earnings, LXEO or NVAX?

Do analysts recommend LXEO or NVAX?

Do institutionals and insiders hold more shares of LXEO or NVAX?

Is LXEO or NVAX more profitable?

Does the media refer more to LXEO or NVAX?

Which has more risk & volatility, LXEO or NVAX?

Summary

How does Lexeo Therapeutics compare to Oric Pharmaceuticals?

Does the media prefer ORIC or LXEO?

Do institutionals & insiders hold more shares of ORIC or LXEO?

Which has better valuation and earnings, ORIC or LXEO?

Which has more risk and volatility, ORIC or LXEO?

Is ORIC or LXEO more profitable?

Do analysts prefer ORIC or LXEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools